While many of its peers recalled their generic versions of Zantac, Sanofi, maker of the branded version in the U.S., bided its time as the FDA investigated the risks posed by a suspected cancer-causing impurity found in the drugs. Now, it has capitulated—sort of.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,